Management of Withdrawal Symptoms After Sublocade Injection
If a patient develops withdrawal symptoms after a Sublocade injection, treat them with additional buprenorphine—either supplemental sublingual buprenorphine or additional doses of extended-release buprenorphine—as the pharmacologic approach to managing buprenorphine-precipitated or breakthrough withdrawal is to administer more buprenorphine, not less.
Immediate Assessment and Monitoring
After any Sublocade injection, the FDA label mandates monitoring patients in a healthcare setting to assess for worsening withdrawal or sedation, with patients' symptoms needing to be stable or improving before discharge 1. This is critical because:
- Withdrawal can occur within 1-4 hours of injection if precipitated withdrawal develops
- The depot formulation solidifies upon contact with body fluids, making removal impossible once injected
- Buprenorphine's high mu-receptor affinity means standard opioid rescue may be ineffective
Treatment Algorithm for Post-Injection Withdrawal
Step 1: Determine Withdrawal Severity and Timing
Within 1-4 hours (Precipitated Withdrawal):
- Use Clinical Opiate Withdrawal Scale (COWS) to quantify severity
- Precipitated withdrawal occurs in approximately 2-7% of patients, with higher risk (13.5%) in those with minimal baseline withdrawal (COWS 0-3) 2
Days to weeks later (Breakthrough Withdrawal):
- May indicate depot removal (surgical procedures like liposuction), inadequate dosing, or rapid metabolism
- Examine injection site for signs of tampering, infection, or surgical intervention 1
- Palpate for depot presence—absence suggests mechanical removal 3
Step 2: Pharmacologic Management
Primary Strategy: Administer Additional Buprenorphine
The evidence strongly supports treating buprenorphine-induced withdrawal with more buprenorphine 4, 5, 6:
- For precipitated withdrawal: Give 2 mg sublingual buprenorphine every 1-2 hours, escalating rapidly as needed. Case reports document successful reversal with total doses of 20 mg within hours 5
- For breakthrough withdrawal: Provide supplemental sublingual buprenorphine 4-8 mg as needed, or consider additional weekly extended-release doses if using Brixadi formulation 7
Pharmacologic Rationale: Buprenorphine's partial agonist activity means increasing the dose will eventually saturate mu-receptors and provide relief. The high receptor affinity (higher than full agonists) means full opioid agonists are generally ineffective for rescue 8.
Step 3: Adjunctive Symptomatic Management
While additional buprenorphine is the cornerstone, provide symptom-directed support:
- Clonidine for autonomic symptoms (hypertension, tachycardia, sweating)
- Ondansetron for nausea/vomiting
- Loperamide for diarrhea
- NSAIDs for myalgias
- Benzodiazepines (cautiously) for severe anxiety or insomnia
Special Circumstances
Surgical Depot Removal (Iatrogenic Withdrawal)
If the patient underwent surgery (particularly liposuction, abdominoplasty, or procedures at injection sites):
- The depot may have been physically removed, causing acute withdrawal 3
- Immediate management: Administer a new Sublocade injection at a different site (300 mg dose) 3
- Alternative: Bridge with sublingual buprenorphine 8-16 mg daily until next scheduled injection
Inadequate Dosing
If withdrawal symptoms suggest the 100 mg maintenance dose is insufficient:
- FDA labeling permits increasing maintenance dose to 300 mg monthly "for patients in which benefits outweigh risks" 1
- Consider this for patients with high opioid tolerance, fentanyl use history, or persistent breakthrough symptoms
Methadone Conversion Strategy (Hospitalized Patients)
For severe, refractory withdrawal in hospitalized patients, guidelines support converting to methadone 8:
- Start methadone 30-40 mg daily (prevents withdrawal in most patients)
- Methadone binds less tightly to mu-receptors than buprenorphine, allowing additional opioid analgesics to work
- Increase by 5-10 mg increments if withdrawal persists
- Once stabilized, can re-induce buprenorphine when patient is in mild withdrawal
Critical Pitfalls to Avoid
Do not abruptly discontinue buprenorphine therapy without replacement—this increases sensitivity to full agonists and respiratory depression risk 8
Do not attempt to treat with full opioid agonists alone—buprenorphine's high receptor affinity will block their effects, requiring dangerously high doses 8
Do not assume withdrawal is drug-seeking behavior—patients on opioid agonist therapy have legitimate physiologic dependence and require aggressive symptom management 8
Do not re-induce buprenorphine while full agonists are on board—this will precipitate further withdrawal. Patient must be in mild withdrawal before restarting 8
Prevention for Future Injections
- Ensure patients are on stable sublingual buprenorphine (preferably ≥8 mg daily) before first Sublocade injection 1
- For patients not currently on buprenorphine, give initial 4 mg sublingual dose before injection 1
- Wait for objective withdrawal signs (COWS ≥4-7) before initiating in opioid-dependent patients 2
- Document injection sites and warn patients/surgeons about depot location before any surgical procedures 3
- Consider prescribing naloxone for overdose risk, as patients remain at risk for relapse 1
The key principle is that buprenorphine withdrawal is best treated with buprenorphine itself, whether through rapid sublingual dosing or repeat extended-release injection, combined with aggressive symptomatic support.